Bioject Enters Into Strategic Alliance With MPI Research

Bioject Medical Technologies (Bioject) has established a strategic alliance with MPI Research. It allows Bioject to gain access to a range of capabilities and resources needed to explore its drug and device opportunities, including access to pharmacologic, analytical, safety and other preclinical testing resources available at MPI Research.

The strategic alliance offers MPI Research the opportunity to provide Bioject’s needle-free technology as an alternate delivery option to current drug/biologic manufacturers.

Moreover, the alliance also increases the possibility for Bioject and MPI Research to secure government sponsored grants or funding directed at improvements in drug and device or vaccine and device-based treatments, which could also lead to potential new drug and device combinations.

Ralph Makar, president and CEO of Bioject, said: “We look forward to our new strategic alliance with MPI Research, which adds the much needed resource capabilities that we have been seeking as a first step in advancing our new drug and device business strategy.

“This is a positive step forward for both organisations and allows each partner to leverage the strengths, resources and technologies available that we believe will lead to additional new business opportunities for both companies. We are excited and enthusiastic about the potential for the future.”